Reuters logo
BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib
December 26, 2017 / 12:43 PM / 21 days ago

BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib

Dec 26 (Reuters) - Agios Pharmaceuticals Inc:

* AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION

* AGIOS PHARMACEUTICALS INC - EXPECTS TO INITIATE PHASE 1 TRIAL FOR AG-270 IN Q1 OF 2018

* AGIOS PHARMACEUTICALS INC - ‍ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AG-270 TARGETING MTAP-DELETED TUMORS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below